Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Dermatology

Journal Scan / Research · October 27, 2024

Pembrolizumab as a First-Line Treatment for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma

American Journal of Clinical Dermatology

 

Additional Info

Disclosure statements are available on the authors' profiles:

American Journal of Clinical Dermatology
Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study
Am J Clin Dermatol 2024 Oct 08;[EPub Ahead of Print], L Mortier, L Villabona, B Lawrence, A Arance, MO Butler, M Beylot-Barry, P Saiag, M Samimi, PA Ascierto, F Spada, M De Pontville, M Maio, A Berrocal, E Espinosa, J Capdevila, M Levin, D Das, C Krepler, D Grebennik, V Chiarion-Sileni

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading